Compugen Ltd (CGEN)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014334)
◆英語タイトル:Compugen Ltd (CGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014334
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:49
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:イスラエル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥56,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥84,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Compugen Ltd (Compugen) is a drug discovery company that develops medicines for immuno-oncology and autoimmune diseases. The company’s immuno-oncology pipeline comprises CGEN-15001T, CGEN-15022, CGEN-15022, CGEN-15029, target candidates, immuno-modulatory target candidates and ADC target candidates. Its drug development process include target discovery, target validation and predictive discovery programs. The company also offers targets for antibody drug conjugate therapy. It offers predictive theories for integration process containing biology knowledge, genome and proteome analysis, and experimental and disease data; computational model; and novel and non-novel candidates. Compugen is headquartered in Holon, Israel.

Compugen Ltd (CGEN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Compugen Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Compugen Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Compugen Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Compugen Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Compugen Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Compugen Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Compugen Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Neviah Genomics Raises Additional Funds through Venture Financing 12
Partnerships 13
Compugen Enters into Research Agreement with Mount Sinai Innovation Partners 13
Compugen Enters into Research Agreement with Johns Hopkins University School of Medicine 14
BioLineRx Enters Into Co-Development Agreement With Compugen 15
Compugen Enters Into Co-Marketing Agreement With DiscoveRx 16
Licensing Agreements 17
Compugen Enters into Licensing Agreement with Bayer HealthCare for Cancer Immunotherapies 17
Equity Offering 18
Compugen Completes Public Offering Of Shares For US$72.5 Million 18
Evogene Completes Public Offering Of Shares For US$84.8 Million 19
Keddem Bioscience Announces Private Placement Of Common Stock For US$15 Million 20
Compugen Announces Private Placement Of Shares For US$8 Million 21
Compugen Files Registration Statement For Public Offering Of Common Stock For US$40 Million 22
Compugen Ltd – Key Competitors 23
Compugen Ltd – Key Employees 24
Compugen Ltd – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Affiliate 25
Joint Venture 26
Recent Developments 27
Financial Announcements 27
Nov 07, 2017: Compugen Reports Third Quarter 2017 Results 27
Aug 02, 2017: Compugen Reports Second Quarter 2017 Results 28
May 09, 2017: Compugen Reports First Quarter 2017 Results 29
Feb 15, 2017: Compugen Reports Fourth Quarter and Calendar Year 2016 Results 30
Nov 07, 2016: Compugen Reports 3rd Quarter 2016 Financial Results 31
Aug 02, 2016: Compugen Reports 2nd Quarter 2016 Financial Results 32
May 10, 2016: Compugen Reports First Quarter 2016 Financial Results 33
Feb 09, 2016: Compugen Reports Fourth Quarter and Calendar 2015 Results 34
Corporate Communications 35
Aug 02, 2017: Compugen Welcomes Paul Sekhri as its New Chairman of the Board 35
Mar 08, 2017: Compugen Announces Addition of Prof. Miriam Merad to Its Scientific Advisory Board 36
Product News 37
Oct 09, 2017: A New Immunomodulatory Target Discovered by Compugen Demonstrates Potential for First-in-Class Cancer Therapy 37
Aug 30, 2016: Compugen Discloses Development of Enhanced LINKS Platform Utilized for the Discovery of Myeloid Targets for Cancer Immunotherapy 38
07/26/2017: Compugen Provides Update on its Cancer Drug Candidate CGEN-15022 39
06/22/2016: Compugen Discloses Lead Therapeutic Candidate for CGEN-15029 Immuno-Oncology Program 40
03/28/2017: Compugen Announces Lead Therapeutic Candidate COM902 for CGEN-15137/TIGIT Immuno-Oncology Program 41
03/02/2017: Compugen Announces Presentations of COM701 Immuno-oncology Pipeline Product and Predictive Discovery Methodology for Novel Immune Checkpoints at AACR 42
02/29/2016: Compugen Presents Results for CGEN-15029 Immuno-Oncology Therapeutic Program 43
01/04/2017: Compugen’s CGEN-15001 Demonstrates Restoration of Immune Tolerance in Autoimmunity 44
Clinical Trials 45
May 04, 2017: Compugen to Present COM701 Checkpoint Product Candidate for Immuno-Oncology at ASCO 45
Dec 07, 2016: Compugen Discloses its Cancer Immunotherapy Program Targeting TIGIT Immune Checkpoint 46
Nov 11, 2016: Compugen Immune Checkpoint Program Demonstrates Potential for Development of New Cancer Immunotherapy Treatments 47
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
Compugen Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Compugen Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Compugen Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Compugen Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Compugen Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Compugen Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Compugen Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Neviah Genomics Raises Additional Funds through Venture Financing 12
Compugen Enters into Research Agreement with Mount Sinai Innovation Partners 13
Compugen Enters into Research Agreement with Johns Hopkins University School of Medicine 14
BioLineRx Enters Into Co-Development Agreement With Compugen 15
Compugen Enters Into Co-Marketing Agreement With DiscoveRx 16
Compugen Enters into Licensing Agreement with Bayer HealthCare for Cancer Immunotherapies 17
Compugen Completes Public Offering Of Shares For US$72.5 Million 18
Evogene Completes Public Offering Of Shares For US$84.8 Million 19
Keddem Bioscience Announces Private Placement Of Common Stock For US$15 Million 20
Compugen Announces Private Placement Of Shares For US$8 Million 21
Compugen Files Registration Statement For Public Offering Of Common Stock For US$40 Million 22
Compugen Ltd, Key Competitors 23
Compugen Ltd, Key Employees 24
Compugen Ltd, Subsidiaries 25
Compugen Ltd, Affiliate 25
Compugen Ltd, Joint Venture 26

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Compugen Ltd (CGEN)-製薬・医療分野:企業M&A・提携分析(Compugen Ltd (CGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆